Fresenius Medical Care AG & Co. (FMS) Rating Increased to Buy at Zacks Investment Research

Fresenius Medical Care AG & Co. (NYSE:FMS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday. The firm currently has a $62.00 target price on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 12.89% from the company’s current price.

According to Zacks, “Fresenius has had a favorable run on the bourse over the last year. A solid full-year guidance instills our confidence on the stock. We believe this is in tune with the ‘Growth Strategy 2020’, under which it aims to boost revenues to $28 billion by 2020, corresponding to an average annual growth rate of around 10%. A wide range of dialysis products, initiatives to gain market traction, strengthened international foothold, strategic acquisitions and divestments act as major catalysts. On the flipside, lackluster performance by the renal pharmaceutical segment is likely to dent Latin-American revenues in the coming quarters. Having a strong international foothold, Fresenius faces the brunt of stringent regulations in almost every country in which it operates. Thus, it has to fulfill specific legal requirements that include tough antitrust laws. Regulatory hurdles and competition in the niche markets are major headwinds.”

Several other research analysts have also recently weighed in on the stock. UBS Group upgraded shares of Fresenius Medical Care AG & Co. from a “sell” rating to a “neutral” rating in a research note on Thursday, January 4th. Nord/LB reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Tuesday, January 2nd. SunTrust Banks set a $62.00 price target on shares of Fresenius Medical Care AG & Co. and gave the stock a “buy” rating in a research note on Thursday, December 21st. DZ Bank reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Monday, December 18th. Finally, Morgan Stanley cut shares of Fresenius Medical Care AG & Co. from an “overweight” rating to an “equal weight” rating in a research note on Monday, December 11th. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $56.00.

Fresenius Medical Care AG & Co. (NYSE FMS) traded up $0.45 during trading hours on Thursday, reaching $54.92. 111,300 shares of the company’s stock were exchanged, compared to its average volume of 149,491. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.98 and a current ratio of 1.22. Fresenius Medical Care AG & Co. has a fifty-two week low of $40.02 and a fifty-two week high of $55.30. The company has a market cap of $33,384.88, a P/E ratio of 24.63, a PEG ratio of 2.25 and a beta of 0.45.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its earnings results on Thursday, November 2nd. The company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.02). Fresenius Medical Care AG & Co. had a return on equity of 11.51% and a net margin of 7.04%. equities analysts predict that Fresenius Medical Care AG & Co. will post 2.38 earnings per share for the current year.

Institutional investors have recently modified their holdings of the company. UBS Asset Management Americas Inc. boosted its stake in shares of Fresenius Medical Care AG & Co. by 3.6% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock worth $114,000 after acquiring an additional 81 shares during the last quarter. YorkBridge Wealth Partners LLC boosted its stake in shares of Fresenius Medical Care AG & Co. by 19.4% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock worth $222,000 after acquiring an additional 749 shares during the last quarter. Stifel Financial Corp purchased a new position in shares of Fresenius Medical Care AG & Co. during the 2nd quarter worth $225,000. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Fresenius Medical Care AG & Co. during the 3rd quarter worth $239,000. Finally, Pacer Advisors Inc. boosted its stake in shares of Fresenius Medical Care AG & Co. by 37.6% during the 3rd quarter. Pacer Advisors Inc. now owns 5,105 shares of the company’s stock worth $250,000 after acquiring an additional 1,394 shares during the last quarter. Institutional investors and hedge funds own 3.03% of the company’s stock.

WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/01/18/fresenius-medical-care-ag-co-fms-rating-increased-to-buy-at-zacks-investment-research.html.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Get a free copy of the Zacks research report on Fresenius Medical Care AG & Co. (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply